Total Payments
$94,657
2024 Payments
$6,775
Companies
15
Transactions
112
Medicare Patients
144
Medicare Billing
$21,370
Payment Breakdown by Category
Consulting$45,011 (47.6%)
Travel$28,734 (30.4%)
Research$14,003 (14.8%)
Other$4,335 (4.6%)
Food & Beverage$2,515 (2.7%)
Education$59.56 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,011 | 20 | 47.6% |
| Travel and Lodging | $28,734 | 19 | 30.4% |
| Unspecified | $14,003 | 17 | 14.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,335 | 3 | 4.6% |
| Food and Beverage | $2,515 | 51 | 2.7% |
| Education | $59.56 | 2 | 0.1% |
Payments by Type
General
$80,655
95 transactions
Research
$14,003
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $29,011 | 59 | $0 (2022) |
| Celgene Corporation | $17,111 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $15,019 | 12 | $0 (2023) |
| Genentech USA, Inc. | $12,872 | 7 | $0 (2022) |
| EMD Serono Research & Development Institute, Inc. | $8,064 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $7,404 | 5 | $0 (2024) |
| F. Hoffmann-La Roche AG | $2,921 | 4 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,020 | 1 | $0 (2020) |
| Genentech, Inc. | $509.85 | 3 | $0 (2022) |
| GENZYME CORPORATION | $370.29 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,775 | 6 | E.R. Squibb & Sons, L.L.C. ($5,040) |
| 2023 | $34,771 | 13 | Celgene Corporation ($16,957) |
| 2022 | $9,327 | 28 | Genentech USA, Inc. ($4,263) |
| 2021 | $9,502 | 6 | Biogen, Inc. ($5,517) |
| 2020 | $6,179 | 5 | Genentech USA, Inc. ($4,624) |
| 2019 | $912.83 | 1 | Biogen, Inc. ($912.83) |
| 2018 | $23,220 | 39 | Biogen, Inc. ($15,291) |
| 2017 | $3,972 | 14 | Biogen, Inc. ($2,509) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $564.69 | Research |
| Study: Impact of Step-Therapy Policies on Clinical Outcomes and Healthcare Resource Utilization Among Medicaid Beneficiaries Living With Multiple Sclerosis (MS) • Category: Immunology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,041.63 | Research |
| Study: Impact of step-therapy policies on clinical outcomes, healthcare resource utilization and costs among Medicaid beneficiaries living with multiple sclerosis • Category: Immunology | ||||||
| 09/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $78.42 | General |
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| 05/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 11/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,170.00 | General |
| 07/01/2023 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $8,450.65 | General |
| 06/30/2023 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $8,474.65 | General |
| 06/30/2023 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | — | Cash or cash equivalent | $6,217.00 | Research |
| Study: MAYZENT Study Related Review Article Writing Support • Category: Neurology | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $850.40 | Research |
| Study: Disparities in Telemedicine Utilization for Multiple Sclerosis Care | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $463.90 | Research |
| Study: Disparities in Telemedicine Utilization for Multiple Sclerosis Care | ||||||
| 06/30/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $48.90 | General |
| 06/30/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.80 | General |
| 06/30/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $8.45 | General |
| 06/30/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $8.45 | General |
| 05/09/2023 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,950.00 | General |
| 03/09/2023 | EMD Serono Research & Development Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.82 | General |
| 03/07/2023 | EMD Serono Research & Development Institute, Inc. | — | Food and Beverage | Cash or cash equivalent | $95.83 | General |
| 12/13/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $527.02 | General |
| 12/07/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $518.22 | General |
| 10/25/2022 | Genentech USA, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $2,585.00 | General |
| Category: Immunology | ||||||
| 10/25/2022 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $178.09 | General |
| Category: Immunology | ||||||
| 09/26/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $75.75 | General |
| Category: Neuroscience | ||||||
| 08/26/2022 | Genentech, Inc. | OCREVUS (Biological) | Travel and Lodging | In-kind items and services | $396.29 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MAYZENT Study Related Review Article Writing Support | Novartis Pharmaceuticals Corporation | $6,217 | 1 |
| KOL MS Data Interpretation New Ask | Biogen, Inc. | $2,370 | 1 |
| Disparities in Telemedicine Utilization for Multiple Sclerosis Care | F. Hoffmann-La Roche AG | $1,314 | 2 |
| Impact of step-therapy policies on clinical outcomes, healthcare resource utilization and costs among Medicaid beneficiaries living with multiple sclerosis | F. Hoffmann-La Roche AG | $1,042 | 1 |
| MS PATHS Normative Sub-Study | Biogen, Inc. | $973.12 | 9 |
| MSPT Device Usability Study | Biogen, Inc. | $912.83 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $609.36 | 1 |
| Impact of Step-Therapy Policies on Clinical Outcomes and Healthcare Resource Utilization Among Medicaid Beneficiaries Living With Multiple Sclerosis (MS) | F. Hoffmann-La Roche AG | $564.69 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 13 | $5,447 | $897.96 |
| 2022 | 1 | 21 | 27 | $10,067 | $1,869 |
| 2021 | 3 | 53 | 97 | $52,803 | $8,606 |
| 2020 | 4 | 59 | 115 | $64,064 | $9,997 |
Total Patients
144
Total Services
252
Medicare Billing
$21,370
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 13 | $5,447 | $897.96 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 27 | $10,067 | $1,869 | 18.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 50 | $26,850 | $4,111 | 15.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $13,516 | $2,356 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 24 | 34 | $12,437 | $2,139 | 17.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 74 | $38,554 | $6,038 | 15.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $14,000 | $2,158 | 15.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 13 | $6,534 | $971.66 | 14.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 14 | $4,976 | $829.22 | 16.7% |
About Dr. Daniel Ontaneda, M.D
Dr. Daniel Ontaneda, M.D is a Neurology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2008. The National Provider Identifier (NPI) number assigned to this provider is 1649444142.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Ontaneda, M.D has received a total of $94,657 in payments from pharmaceutical and medical device companies, with $6,775 received in 2024. These payments were reported across 112 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($45,011).
As a Medicare-enrolled provider, Ontaneda has provided services to 144 Medicare beneficiaries, totaling 252 services with total Medicare billing of $21,370. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Cleveland, OH
- Active Since 04/15/2008
- Last Updated 04/02/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649444142
Products in Payments
- OCREVUS (Biological) $13,382
- MAYZENT (Drug) $13,082
- Ocrevus (Biological) $1,606
- TYSABRI (Biological) $1,461
- GILENYA (Drug) $825.28
- AUBAGIO (Drug) $370.29
- ZEPOSIA (Drug) $220.71
- NO PRODUCT DISCUSSED (Drug) $119.31
- COPAXONE (Drug) $76.20
- ULTOMIRIS (Biological) $50.00
- Rebif (Biological) $24.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Cleveland
Imad Najm, Md, MD
Neurology — Payments: $428,375
Neurology $428,375
Dr. Robert Bermel, M.d, M.D
Neurology — Payments: $427,113
Neurology $427,113
Robert Fox, Md, MD
Neurology — Payments: $403,845
Neurology $403,845
Benjamin Walter, Md, MD
Neurology — Payments: $384,235
Neurology $384,235
Dr. Mary Willis, M.d, M.D
Neurology — Payments: $361,341
Neurology $361,341
Mary Rensel, Md, MD
Neurology — Payments: $288,222
Neurology $288,222